American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 779-789 , May 2009

Effect of the MTHFR C677T and A1298C Polymorphisms on Survival in Patients With Advanced CKD and ESRD: A Prospective Study

Received 7 October 2008 ,Accepted 30 December 2008.

References 

  1. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–113
  2. Cook RJ. Folate metabolism. In:  Carmel R,  Jacobsen DW editor. Homocysteine in Health and Disease. Cambridge, UK: University Press; 2001;p. 113–134
  3. Weisberg IS, Jacques PF, Selhub J, et al. The 1298A→C polymorphism in methylenetetrahydrofolate reductase (MTHFR): In vitro expression and association with homocysteine. Atherosclerosis. 2001;156:409–415
  4. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ. 2002;325:1202–1206
  5. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: A meta-analysis. JAMA. 2002;288:2023–2031
  6. Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: Does totality of evidence support causal role for homocysteine and preventive potential of folate?. BMJ. 2005;331:1053–1058
  7. Pereira AC, Miyakawa AA, Lopes NH, et al. Dynamic regulation of MTHFR mRNA expression and C677T genotype modulate mortality in coronary artery disease patients after revascularization. Thromb Res. 2007;121:25–32
  8. Garcia-Pinilla JM, Espinosa-Caliani S, Jimenez-Navarro M, et al. Influence of 677 C→T polymorphism of methylenetetrahydrofolate reductase on medium-term prognosis after acute coronary syndromes. Tex Heart Inst J. 2007;34:142–147
  9. Bathum L, von Bornemann Hjelmborg J, Christiansen L, et al. Methylenetetrahydrofolate reductase 677C→T and methionine synthase 2756A→G mutations: No impact on survival, cognitive functioning, or cognitive decline in nonagenarians. J Gerontol A Biol Sci Med Sci. 2007;62:196–201
  10. Weisberg I, Tran P, Christensen B, et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998;64:169–172
  11. Kolling K, Ndrepepa G, Koch W, et al. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. Am J Cardiol. 2004;93:1201–1206
  12. Martin DN, Boersma BJ, Howe TM, et al. Association of MTHFR gene polymorphisms with breast cancer survival. BMC Cancer. 2006;6:257
  13. Fodinger M, Mannhalter C, Wolfl G, et al. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int. 1997;52:517–523
  14. Pernod G, Bosson JL, Golshayan D, et al. Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort. Kidney Int. 2006;69:1424–1430
  15. Wrone EM, Zehnder JL, Hornberger JM, et al. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int. 2001;60:1106–1113
  16. Fletcher O, Kessling AM. MTHFR association with arteriosclerotic vascular disease?. Hum Genet. 1998;103:11–21
  17. Aucella F, Margaglione M, Grandone E, et al. The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: Results of a multicentre prospective study. Nephrol Dial Transplant. 2005;20:382–386
  18. Kimura H, Gejyo F, Suzuki S, et al. The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients. J Am Soc Nephrol. 2000;11:885–893
  19. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA. 2007;298:1163–1170
  20. Yi P, Pogribny I, Jill James S. Multiplex PCR for simultaneous detection of 677 C→T and 1298 A→C polymorphisms in methylenetetrahydrofolate reductase gene for population studies of cancer risk. Cancer Lett. 2002;181:209–213
  21. Hougaard P. Analysis of Multivariate Survival Data. In: New York, NY: Springer; 2000;p. 72–7384-85
  22. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. (ed 1). New York, NY: Springer; 2000;
  23. Thomson PC, Stirling CM, Geddes CC, et al. Vascular access in haemodialysis patients: A modifiable risk factor for bacteraemia and death. QJM. 2007;100:415–422
  24. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111–128
  25. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In:  Crever CR,  Beaudet AL,  Sly WS,  Valle D editor. The Metabolic Basis of Inherited Disease. (ed 7). New York, NY: McGraw-Hill; 1994;p. 1279–1327
  26. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease (Probable benefits of increasing folic acid intakes). JAMA. 1995;274:1049–1057
  27. Robinson K, Gupta A, Dennis V, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation. 1996;94:2743–2748
  28. Wilcken DE, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis. 1997;20:295–300
  29. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–236
  30. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients (A prospective study). Arterioscler Thromb Vasc Biol. 1997;17:2554–2558
  31. Brattstrom L, Zhang Y, Hurtig M, et al. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis. 1998;141:315–319
  32. Eikelboom JW, Lonn E, Genest J, et al. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med. 1999;131:363–375
  33. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–575
  34. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–1588
  35. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567–1577
  36. Loscalzo J. Homocysteine trials—Clear outcomes for complex reasons. N Engl J Med. 2006;354:1629–1632
  37. Rozen R. Polymorphisms of folate and cobalamin metabolism. In:  Carmel R,  Jacobsen D editor. Homocysteine in Health and Disease. Cambridge, UK: Cambridge University; 2001;p. 259–269
  38. Schneider JA, Rees DC, Liu YT, et al. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet. 1998;62:1258–1260
  39. Stevenson RE, Schwartz CE, Du YZ, et al. Differences in methylenetetrahydrofolate reductase genotype frequencies, between whites and blacks. Am J Hum Genet. 1997;60:229–230
  40. Robinson BM, Joffe MM, Pisoni RL, et al. Revisiting survival differences by race and ethnicity among hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol. 2006;17:2910–2918
  41. Boger CA, Stubanus M, Haak T, et al. Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy. Nephrol Dial Transplant. 2007;22:154–162

 A list of author affiliations appears at the end of this article.

 A list of the Veterans Affairs Site Investigators appears at the end of this article.

 Originally published online as doi:10.1053/j.ajkd.2008.12.023 on March 9, 2009.

 Trial Registration: www.clinicaltrials.gov; study number: NCT00032435.

 Because an author of this manuscript is an editor for AJKD, the peer-review and decision-making processes were handled entirely by an Associate Editor (Barbara Murphy, MD, Mount Sinai School of Medicine) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

PII: S0272-6386(09)00061-4

doi: 10.1053/j.ajkd.2008.12.023

American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 779-789 , May 2009

Article Tools

* Image Usage & Resolution